Head-to-head · WeighScore
bmiMD vs telos rx
By GLP-1 ScorecardUpdated
Score comparison
telos rx has the higher recorded score — 85.4/100 to 79.2/100.
telos rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telos offers compounded oral and injectable formats; discounted plans can carry early-exit adjustments.
Before you choose
Before comparing the headline prices, the bmiMD review and the telos rx review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, bmiMD vs TRYM Health and Breeze Meds vs telos rx compare each of them with another graded program, and the list of alternatives to bmiMD ranks the programs closest to bmiMD on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | bmiMD | telos rx |
|---|---|---|
| WeighScore | 79.2/100 | 85.4/100 |
| Grade | C+ | B |
| Site position | #27 | #13 |
| Semaglutide | $129/mo on the one-month plan ($99/mo equivalent with $1,188 prepaid for 12 months) | Advertised from $99/month injectable; plan-dependent; selected bill unverified. |
| Tirzepatide | $179/mo on the one-month plan ($139/mo equivalent with $1,668 prepaid for 12 months) | Advertised from $139/month injectable; from $116/month microdosed injection; selected bills unverified. |
| Coverage | All 50 states | Advertises all 50 states; pharmacy and formulation availability varies. |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Strengths
- Advertises the same price across prescribed doses for each selected injection plan
- Publishes compounded semaglutide and tirzepatide injection plans
- Every rung of both ladders is published with the total charge beside each per-month figure
- All 50 states
What to consider
- The pricing block opens on the 3-Month tab, so the figure a reader meets first is a commitment rate rather than a month
- The annual $99 and $139 monthly equivalents require $1,188 or $1,668 paid upfront for 12 months
- A higher $229 and $349 monthly figure is printed beside every plan price under a standing LIMITED TIME label, with no published basis
- Neither the compounding pharmacy nor the prescribing group is named on the product pages
Strengths
- Names its care organization and pharmacy partners
- Oral and injectable compounded options
What to consider
- Early cancellation can reprice supplied months
- Entity, denial-refund and lab terms conflict
- Current oral invoice and renewal price unverified
Featured provider
bmiMD
Factor scores not reassessed.bmiMD scores 79.2/100 (C+). bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.